Key Takeaway: Precision BioSciences, a gene editing company, will present at the JonesTrading Healthcare Seaside Summit. This event highlights their proprietary ARCUS platform, which is focused on developing in vivo gene editing therapies. The presentation aims to enhance the company's visibility in the healthcare sector.
Price reaction · baseline $9.2 (2024-07-05 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+1.1%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is actively participating in significant industry events.
The presentation showcases their innovative ARCUS platform.
Engagement at the summit may enhance visibility and partnerships.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Jul. 8, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading
Frequently Asked Questions
What is the focus of Precision BioSciences?
Precision BioSciences focuses on developing in vivo gene editing therapies.
Where will Precision BioSciences present?
They will present at the JonesTrading Healthcare Seaside Summit.
What platform does Precision BioSciences utilize?
They utilize their proprietary ARCUS platform for gene editing.